Search Results - "CIULEANU, T"

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden by Hellmann, Matthew D, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S, Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J, Geese, William J, Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis

“…Among patients with non–small-cell lung cancer and tumors containing at least 10 mutations per megabase, the 1-year progression-free survival rate was 43% with…”
Get full text

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study by Douillard, J-Y, Ostoros, G, Cobo, M, Ciuleanu, T, McCormack, R, Webster, A, Milenkova, T

“…Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and safety/tolerability of first-line gefitinib in Caucasian patients with…”
Get full text

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study by Tabernero, J., Hozak, R.R., Yoshino, T., Cohn, A.L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D.C., Prausová, J., Muro, K., Siegel, R.W., Konrad, R.J., Ouyang, H., Melemed, S.A., Ferry, D., Nasroulah, F., Van Cutsem, E.

“…The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody…”
Get full text

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update by Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

“…To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated…”
Get full text

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study by Ferris, R.L., Haddad, R., Even, C., Tahara, M., Dvorkin, M., Ciuleanu, T.E., Clement, P.M., Mesia, R., Kutukova, S., Zholudeva, L., Daste, A., Caballero-Daroqui, J., Keam, B., Vynnychenko, I., Lafond, C., Shetty, J., Mann, H., Fan, J., Wildsmith, S., Morsli, N., Fayette, J., Licitra, L.

“…Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head…”
Get full text

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis by Borghaei, H., Ciuleanu, T.-E., Lee, J.-S., Pluzanski, A., Caro, R. Bernabe, Gutierrez, M., Ohe, Y., Nishio, M., Goldman, J., Ready, N., Spigel, D.R., Ramalingam, S.S., Paz-Ares, L.G., Gainor, J.F., Ahmed, S., Reck, M., Maio, M., O’Byrne, K.J., Memaj, A., Nathan, F., Tran, P., Hellmann, M.D., Brahmer, J.R.

“…First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical…”
Get full text

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer by Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A

“…Although pembrolizumab has appeared to be more effective than chemotherapy in patients with lung cancer whose tumors had at least 50% PD-L1–positive cells,…”
Get full text

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 by Spigel, D.R., Vicente, D., Ciuleanu, T.E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Luft, A., Wolf, J., Antonia, S., Nakagawa, K., Fairchild, J., Baudelet, C., Pandya, D., Doshi, P., Chang, H., Reck, M.

“…Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously…”
Get full text

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer by Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C.J.A., Strickland, A.H., Wilson, G., Ciuleanu, T.E., Roman, L., Van Cutsem, E., Tian, Y., Sidhu, R.

“…The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased…”
Get full text

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation by Fountzilas, G., Ciuleanu, E., Bobos, M., Kalogera-Fountzila, A., Eleftheraki, A.G., Karayannopoulou, G., Zaramboukas, T., Nikolaou, A., Markou, K., Resiga, L., Dionysopoulos, D., Samantas, E., Athanassiou, H., Misailidou, D., Skarlos, D., Ciuleanu, T.

“…Concomitant administration of radiation therapy (RT) and chemotherapy with cisplatin (CCRT) is considered standard treatment in patients with locally advanced…”
Get full text

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study by Brodowicz, T., Ciuleanu, T.E., Radosavljevic, D., Shacham-Shmueli, E., Vrbanec, D., Plate, S., Mrsic-Krmpotic, Z., Dank, M., Purkalne, G., Messinger, D., Zielinski, C.C.

“…This randomized phase II study investigated first-line chemotherapy plus cetuximab administered every second week in KRAS wild-type metastatic colorectal…”
Get full text

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1) by Ramalingam, S., Goss, G., Rosell, R., Schmid-Bindert, G., Zaric, B., Andric, Z., Bondarenko, I., Komov, D., Ceric, T., Khuri, F., Samarzija, M., Felip, E., Ciuleanu, T., Hirsh, V., Wehler, T., Spicer, J., Salgia, R., Shapiro, G., Sheldon, E., Teofilovici, F., Vukovic, V., Fennell, D.

“…This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to…”
Get full text

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study by Yoshino, T., Portnoy, D.C., Obermannová, R., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., García-Alfonso, P., Cohn, A.L., Van Cutsem, E., Yamazaki, K., Lonardi, S., Muro, K., Kim, T.W., Yamaguchi, K., Grothey, A., O’Connor, J., Taieb, J., Wijayawardana, S.R., Hozak, R.R., Nasroulah, F., Tabernero, J.

“…Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC)…”
Get full text

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression by Obermannová, R., Van Cutsem, E., Yoshino, T., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., Garcia Alfonso, P., Portnoy, D., Cohn, A., Yamazaki, K., Clingan, P., Lonardi, S., Kim, T.W., Yang, L., Nasroulah, F., Tabernero, J.

“…The RAISE phase III clinical trial demonstrated that ramucirumab + FOLFIRI improved overall survival (OS) [hazard ratio (HR) = 0.844, P = 0.0219] and…”
Get full text

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial by Borghaei, H, O'Byrne, K J, Paz-Ares, L, Ciuleanu, T-E, Yu, X, Pluzanski, A, Nagrial, A, Havel, L, Kowalyszyn, R D, Valette, C A, Brahmer, J R, Reck, M, Ramalingam, S S, Zhang, L, Ntambwe, I, Rabindran, S K, Nathan, F E, Balli, D, Wu, Y-L

“…In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC)…”
Get full text

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01) by Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., Keus, R., Hatton, M., Videtic, G.M., Senan, S., Wolfson, A., Jones, R., Arriagada, R., Quoix, E., Dunant, A.

“…We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the…”
Get full text

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy by Coudert, B., Ciuleanu, T., Park, K., Wu, Y.-L., Giaccone, G., Brugger, W., Gopalakrishna, P., Cappuzzo, F.

“…In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free…”
Get full text

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma by Ciuleanu, T., Bazin, I., Lungulescu, D., Miron, L., Bondarenko, I., Deptala, A., Rodriguez-Torres, M., Giantonio, B., Fox, N.L., Wissel, P., Egger, J., Ding, M., Kalyani, R.N., Humphreys, R., Gribbin, M., Sun, W.

“…This randomized, double-blind, placebo-controlled, phase II study evaluated the efficacy and safety of mapatumumab (a human agonistic monoclonal antibody…”
Get full text

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer by Del Campo, J. M., Roszak, A., Bidzinski, M., Ciuleanu, T. E., Hogberg, T., Wojtukiewicz, M. Z., Poveda, A., Boman, K., Westermann, A. M., Lebedinsky, C.

“…Background: This randomized, open-label, phase II clinical trial evaluated the optimal regimen of trabectedin administered every 3 weeks in patients with…”
Get full text

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial by Camerini, A., Morabito, A., Montanino, A., Bernabé, R., Grossi, F., Ramlau, R., Ciuleanu, T.-E., Ceresoli, G.-L., Pasello, G., de Marinis, F., Bosch-Barrera, J., Laundreau, P., Gautier, S., Ta Thanh Minh, C., Kowalski, D.

“…To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) in advanced non-small-cell lung cancer (NSCLC) in patients unfit for…”
Get full text